667 related articles for article (PubMed ID: 9808576)
1. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Zhang X; Ren R
Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
[TBL] [Abstract][Full Text] [Related]
2. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
[TBL] [Abstract][Full Text] [Related]
4. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
[TBL] [Abstract][Full Text] [Related]
5. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
Zhang X; Wong R; Hao SX; Pear WS; Ren R
Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
[TBL] [Abstract][Full Text] [Related]
6. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.
Jiang X; Ng E; Yip C; Eisterer W; Chalandon Y; Stuible M; Eaves A; Eaves CJ
Blood; 2002 Nov; 100(10):3731-40. PubMed ID: 12393460
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Wolff NC; Ilaria RL
Blood; 2001 Nov; 98(9):2808-16. PubMed ID: 11675355
[TBL] [Abstract][Full Text] [Related]
8. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Gross AW; Ren R
Oncogene; 2000 Dec; 19(54):6286-96. PubMed ID: 11175343
[TBL] [Abstract][Full Text] [Related]
9. Disease progression in a murine model of bcr/abl leukemogenesis.
van Etten RA
Leuk Lymphoma; 1993; 11 Suppl 1():239-42. PubMed ID: 8251903
[TBL] [Abstract][Full Text] [Related]
10. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Hao SX; Ren R
Mol Cell Biol; 2000 Feb; 20(4):1149-61. PubMed ID: 10648600
[TBL] [Abstract][Full Text] [Related]
11. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
[TBL] [Abstract][Full Text] [Related]
12. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
Carlo-Stella C; Dotti G; Mangoni L; Regazzi E; Garau D; Bonati A; Almici C; Sammarelli G; Savoldo B; Rizzo MT; Rizzoli V
Blood; 1996 Oct; 88(8):3091-100. PubMed ID: 8874208
[TBL] [Abstract][Full Text] [Related]
13. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
Gross AW; Zhang X; Ren R
Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
[TBL] [Abstract][Full Text] [Related]
14. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
15. The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
Gustafsson K; Jamalpour M; Trinh C; Kharas MG; Welsh M
J Hematol Oncol; 2014 Jun; 7():45. PubMed ID: 24952416
[TBL] [Abstract][Full Text] [Related]
16. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
Zhao RC; Jiang Y; Verfaillie CM
Blood; 2001 Apr; 97(8):2406-12. PubMed ID: 11290604
[TBL] [Abstract][Full Text] [Related]
17. Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Gishizky ML; Johnson-White J; Witte ON
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3755-9. PubMed ID: 8475126
[TBL] [Abstract][Full Text] [Related]
18. Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.
Tomasson MH; Williams IR; Li S; Kutok J; Cain D; Gillessen S; Dranoff G; Van Etten RA; Gilliland DG
Blood; 2001 Mar; 97(5):1435-41. PubMed ID: 11222391
[TBL] [Abstract][Full Text] [Related]
19. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
[TBL] [Abstract][Full Text] [Related]
20. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]